Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 iPSC-derived neural cells
Nicole R. West, Mattias F. Lindberg, Julien Dairou, Shawn MacGregor, Sahith Puthireddy, Laurent Meijer, Anita Bhattacharyya
This study shows that Leucettinib-21 reduces DYRK1A activity in human trisomy 21 neural cells, supporting its potential as a therapeutic for Down syndrome.
bioRxiv · Feb 5, 2026 · PreprintDevelopmental Biology